Commission authorises first treatment for serious chronic lung disease
The Commission granted EU marketing authorisation for ‘brensocatib’, a new active substance for the treatment of chronic progressive lung disease (non-cystic fibrosis bronchiectasis, or NCFB) in patients aged 12 years and older. The estimated number of patients with NCFB in the EU ranges from 400,000 to three million. The disease causes damaged airways and severe …